New insights into the molecular actions of serotonergic antimigraine drugs
- 1 April 2002
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 94 (1-2) , 77-92
- https://doi.org/10.1016/s0163-7258(02)00173-0
Abstract
No abstract availableKeywords
Funding Information
- National Headache Foundation
- Boston Area Diabetes Endocrinology Research Center (DK-25295)
- National Institutes of Health (HD-25969, HL-14388, NS-37386)
This publication has 93 references indexed in Scilit:
- Selective, Orally Active 5-HT1D Receptor Agonists as Potential Antimigraine AgentsJournal of Medicinal Chemistry, 1997
- Serotonin 5‐HT1D and 5‐HT1A Receptors Respectively Mediate Inhibition of Glutamate Release and Inhibition of Cyclic GMP Production in Rat Cerebellum In VitroJournal of Neurochemistry, 1996
- Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headacheNeuroscience Letters, 1995
- Nitric oxide is a key molecule in migraine and other vascular headachesTrends in Pharmacological Sciences, 1994
- Sumatriptan-induced stroke in sagittal sinus thrombosisThe Lancet, 1994
- Regulation of human calcitonin gene transcription by cyclic AMPBiochemical and Biophysical Research Communications, 1992
- Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: A homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificityBiochemical and Biophysical Research Communications, 1992
- Whole Blood and Plasma Histamine in Common MigraineCephalalgia, 1987
- A second human calcitonin/CGRP geneFEBS Letters, 1985
- The Site of Pain Origin During Migraine AttacksCephalalgia, 1981